We conducted this meta-analysis in advanced NSCLC patients treated with PD-1 blockade, focusing on the impact of PD-L1 cutpoint choice on objective response rate (ORR), 1-year PFS, 2-year PFS, 2-year OS, and 3-year OS compared with the outcomes from chemotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.